A Drug Reservoir That Sits in the Bladder Releasing Poorly Soluble Medicines Slowly

This application covers multi-unit drug delivery devices and methods, implantable systems intended for deployment in the urinary bladder that release drug locally over an extended period. The applicant is TARIS Biomedical LLC, now part of Johnson & Johnson.

The Problem

Treating a disease of the bladder with a tablet is inefficient. The drug is absorbed into the bloodstream, distributed through the whole body, and only a fraction reaches the organ that needs it, while the rest produces side effects everywhere else. The alternative, instilling drug directly into the bladder through a catheter, delivers a high local concentration but a very brief one, because the next urination flushes it away.

The devices this application builds on solved the retention problem. Earlier work described drug delivery devices deployed minimally invasively into a cavity such as the bladder, incorporating a retention frame that adopts a low profile for insertion and expands once in place so it resists being expelled during urination. A water permeable tube forms a drug reservoir with an aperture for release, and the drug leaves either by osmotic pumping or by diffusion.

The limitation is chemical. Osmotic pumping, which gives the steadiest and most controllable release, depends on the drug dissolving readily. Highly water soluble drugs such as lidocaine hydrochloride can be released osmotically at therapeutically useful rates for weeks. Drugs of lower solubility cannot, and fall back on diffusion, which offers less control. The specification states the desired improvement directly: to release relatively lower solubility drugs at therapeutically useful rates by osmotic pressure over an extended period, and to deliver a variety of active agents at a selected release kinetics profile.

What This Invention Does

The answer is structural rather than chemical. Instead of a single reservoir with one release behaviour, the device is divided into multiple units, with drug released from the housing according to a first release profile and further units configured to contribute their own. Separating the payload into units that can differ in formulation, aperture arrangement and release mechanism lets a single implant produce a composite release curve rather than the one curve its chemistry would otherwise dictate.

That opens two things at once. A low solubility drug can be arranged so that osmotic release remains viable, by controlling how much dissolved drug is available at each release site rather than relying on bulk solubility. And a release profile can be shaped deliberately, front loaded, steady, or staged, by combining units with different characteristics.

Everything else in the platform carries over. The retention frame still holds the device in place against urination. Insertion and removal are still minimally invasive through the urethra, requiring no surgery. The patient continues normally while the device works for weeks.

Key Features

• Multi-unit construction. The device comprises multiple drug units rather than a single reservoir, allowing composite release behaviour.
• Defined release profiles. Drug is released from the housing according to a first release profile, with further units configured to their own profiles.
• Lower solubility drug handling. The arrangement is aimed at releasing less soluble drugs osmotically at useful rates.
• Retention frame. A frame deploys at low profile and expands in the bladder to resist expulsion during urination.
• Water permeable reservoir tube. Water entry through the tube wall drives osmotic release through defined apertures.
• Minimally invasive deployment. The device is placed and retrieved through the urethra without surgery.

Who Is Behind It

TARIS Biomedical was founded in 2008 by Michael Cima and Robert Langer, both of MIT and both central figures in drug delivery engineering, and raised around 109 million United States dollars before being acquired by Johnson & Johnson in December 2019. Its lead programme, TAR-200, uses the platform to deliver chemotherapy continuously into the bladder for bladder cancer, and moved into the Janssen oncology organisation after the acquisition. The named inventors are Heejin Lee, Karen Daniel and Matthew Sansone.

The application is a divisional of Australian application 2024204252, part of a chain running back through 2021282405, 2019203394 and 2014309012 to the national phase of PCT/US2014/051672 filed in August 2014, with priority from two United States provisionals filed in 2013.

Why It Matters

Bladder cancer is the clearest illustration of why local delivery matters. Non-muscle-invasive disease is treated by instilling drug into the bladder, and it recurs at high rates, so patients face repeated cystoscopies and repeated instillations for years. Replacing intermittent instillation with continuous exposure from an implanted device changes both the pharmacology and the experience of treatment, and TAR-200 has been among the more closely watched programmes in urologic oncology on that basis.

Interstitial cystitis and overactive bladder present a similar logic with different drugs. Both involve chronic symptoms in a single organ treated with systemic medication whose side effects limit dose.

The pattern is worth noting more generally. A device that reaches one organ continuously and the rest of the body barely at all is doing what targeted molecules attempt chemically, but through mechanical means, in a location that happens to be accessible without surgery. The long chain of divisionals stretching from 2013 to 2026 suggests the family remains commercially significant to its owner well after the acquisition.

Related Concepts

• Bladder cancer – the primary indication driving the platform’s development.
• Drug delivery – the broader field of controlling where and when a medicine acts.
• Osmotic pressure – the mechanism behind the steadiest release from these reservoirs.
• Interstitial cystitis – a chronic bladder condition well suited to local delivery.
• Robert Langer – the MIT engineer who co-founded the company and shaped modern drug delivery.
• Medical implant) – the device category this belongs to.

---

AU 2026202074 was published in the Australian Official Journal of Patents on 9 April 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.